Cleveland Clinic researchers are using clinical and mutational data to enhance survival predictions for heterogeneously treated patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
A phase 2 trial of 277 patients with myelodysplastic syndromes including chronic myelomonocytic leukemias found no improvement in overall response rate with azacitidine in combination with lenalidomide or vorinostat.
A transgender patient leads a doctor and his fellow to re-examine the traditional rigid rules of medicine and step outside their comfort zone when the issue of sexual orientation enters the exam room.
When discussing prognosis and treatment options with older leukemia patients, should the focus be on the 10 percent who will survive long-term or the 90 percent who won’t? By trying to prepare patients, do doctors risk dashing their hopes? Mikkael Sekeres, MD, MS, Director of Cleveland Clinic’s Leukemia Program, mulls those difficult questions in his New York Times column.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
For adults with leukemia, five years of disease-free survival technically constitutes a cure. But how should doctor and patient view reaching this milestone? Cautiously, writes oncologist Mikkael Sekeres, MD, MS, Director of Cleveland Clinic’s Leukemia Program, in his New York Times column.
Cleveland Clinic/North American Cooperative Group phase II study shows improved overall response rate with combination therapy in certain patient subgroups with myelodysplastic syndromes and myelomonocytic leukemia.
Doctors bring expertise to NCI-designated cancer center.
Healthcare providers and patients have disparate views of the course of MDS and the value and limitations of treatment. Improved communication and education may increase understanding of the diseases and improve outcomes.